A Study of ZL-1310 in Subjects With Small Cell Lung Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
An open-label, multicenter study of ZL-1310 as a single agent and in combination with Atezolizumab (with and without Carboplatin) to evaluate the safety, efficacy, and pharmacokinetics in subjects with small cell lung cancer
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Nowotwór płuca rozprzestzeniony na inne części ciała lub zaawansowany
- •Wiek co najmniej 18 lat
- •Ogólny stan zdrowia pozwalający na leczenie (skala ECOG 0-1)
- •Mierzalny guz widoczny na zdjęciach (CT, PET/CT lub MRI)
- •Gotowość do pobrania próbki guza lub posiadanie archiwizowanej próbki
- •Oczekiwana długość życia co najmniej 3 miesiące
- •Wcześniejsze leczenie chemioterapią na bazie platyny (w większości grup)
✗ Disqualifies
- •Inny nowotwór (ostatnie 2 lata) wymagający aktywnego leczenia, z wyjątkiem czerniaków skóry lub raka szyjki macicy
- •Brak podpisanej zgody na udział w badaniu
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- October 16, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (41)
City of Hope
Duarte, United States
Yale Cancer Center
New Haven, United States
Sarah Cannon Research Institute
Sarasota, United States
Barbara Ann Karmanos Cancer Institute
Detroit, United States
Hackensack University Medical Center
Hackensack, United States
Roswell Park Comprehensive Cancer Center
Buffalo, United States
Duke University
Durham, United States
University Hospitals Cleveland Medical Center
Cleveland, United States
University of Pittsburgh Hillman Cancer Center
Pittsburgh, United States
Medical University of South Carolina
Charleston, United States
NEXT Virginia
Fairfax, United States
The First Affiliated Hospital of Anhui Medical University
Hefei, China
Beijing Cancer Hospital
Beijing, China
The First Affiliated Hospital of Xiamen University
Xiamen, China
Guangdong Provincial People's Hospital
Guangzhou, China
Harbin Medical University Cancer Hospital
Harbin, China
Henan Cancer Hospital
Zhengzhou, China
Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science & Technology
Wuhan, China
Hunan Cancer Hospital
Changsha, China
Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School
Nanjing, China
The Second Affiliated Hospital of Nanchang University
Nanchang, China
Jilin Cancer Hospital
Ch’ang-ch’un, China
Liaoning Cancer Hospital & Institute
Shenyang, China
The First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, China
Affiliated Cancer Hospital of Shandong First Medical University
Jinan, China
Zhongshan Hospital Fudan University
Shanghai, China
Sichuan Cancer Hospital
Chengdu, China
Rabin Medical Center
Petah Tikva, Israel
The Chaim Sheba Medical Center
Ramat Gan, Israel
Tel Aviv Sourasky Medical Center Ichilov
Tel Aviv, Israel
Instituto de Investigacion Oncologica Vall dHebron (VHIO) - EPON
Barcelona, Spain
Hospital Universitario Ramon y Cajal
Madrid, Spain
Hospital Universitario 12 de Octubre
Madrid, Spain
Hospital Universitario Virgen Macarena
Seville, Spain
Hospital Clinico Universitario de Valencia
Valencia, Spain
Hospital Universitari i Politecnic La Fe de Valencia
Valencia, Spain
START Barcelona_HM Nou Delfos
Barcelona, Spain
START MADRID_Hospital Universitario HM Sanchinarro
Madrid, Spain
Hospital Regional Universitario de Malaga - Hospital General H
Málaga, Spain
NEXT Oncology - Hospital Quironsalud Madrid
Pozuelo de Alarcón, Spain
Hospital Universitario Virgen del Rocio
Seville, Spain
Trial contact
Mona Qureshi
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/24/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.